AbbVie Receives CHMP Positive Opinion for Risankizumab (SKYRIZI(TM)) for the Treatment of Moderate to Severe Plaque Psoriasis

CHMP positive opinion, supported by data from the pivotal Phase 3 program evaluating more than 2,000 patients with moderate to severe plaque psoriasis, will now be reviewed by the European Commission(1-3) In Phase 3 trials, risankizumab achieved signifi... Biopharmaceuticals, Dermatology, Regulatory AbbVie, SKYRIZI, risankizumab, plaque psoriasis, psoriasis
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news